<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-23809" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Jervell and Lange-Nielsen Syndrome</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Pabba</surname>
            <given-names>Krishna</given-names>
          </name>
          <aff>University of Texas at Houston</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Chakraborty</surname>
            <given-names>Rebanta K.</given-names>
          </name>
          <aff>Steward Medical\Good Samaritan Medical</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Krishna Pabba declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Rebanta Chakraborty declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>28</day>
          <month>8</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-23809.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Jervell and Lange Nielsen syndrome is a rare autosomal recessive disorder characterized by bilateral sensorineural hearing loss and a prolonged QTc interval of greater than 500 milliseconds leading to Torsades de pointes and sudden cardiac death. This condition is a form of inherited long QT syndrome. This activity reviews the evaluation and management of Jervell and Lange Nielsen Syndrome and highlights the role of the interprofessional team in educating patients about their prognosis.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Summarize the differential diagnosis of Jervell and Lange Nielsen Syndrome.</p></list-item><list-item><p>Explain the risk factors of developing Jervell and Lange Nielsen Syndrome.</p></list-item><list-item><p>Review the pathophysiology of Jervell and Lange Nielsen Syndrome.</p></list-item><list-item><p>Outline the interprofessional team's strategies for improving care coordination and communication regarding the management of patients with Jervell and Lange Nielsen syndrome.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=23809&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=23809">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-23809.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Jervell and Lange Nielsen syndrome (JLNS) is a rare autosomal recessive disorder characterized by bilateral sensorineural hearing loss and a prolonged QTc interval (usually more than 500 msec), which can lead to Torsades de pointes and sudden cardiac death. It is a form of an inherited long QT syndrome (LQTS). The disease was first described in 1957 by Anton Jervell and Fred Lange-Nielsen in a study of 4 children born with congenital deafness that all suffered from syncope. There was a marked prolongation of the QT interval on electrocardiographic studies with no other identifiable cause for the patient&#x02019;s fainting spells.<xref ref-type="bibr" rid="article-23809.r1">[1]</xref></p>
      </sec>
      <sec id="article-23809.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>JLNS is a congenital disorder that is inherited in an autosomal recessive manner. Most cases are due to deletion mutations in the&#x000a0;<italic toggle="yes">KCNQ1</italic>&#x000a0;(90%) and&#x000a0;<italic toggle="yes">KCNE1</italic>&#x000a0;genes, which encode proteins essential in the potassium channels' functions in the heart and cochlea.<xref ref-type="bibr" rid="article-23809.r2">[2]</xref></p>
      </sec>
      <sec id="article-23809.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>The prevalence of the disorder highly depends on the population studied but overall, it affects from 1 to 6 people per 1,000,000. Due to established genetic traits, Norway and Sweden have an unusually high prevalence at 1 in 200,000.<xref ref-type="bibr" rid="article-23809.r2">[2]</xref>&#x000a0;There have also been reports of an increased incidence in Turkey.<xref ref-type="bibr" rid="article-23809.r3">[3]</xref></p>
      </sec>
      <sec id="article-23809.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>The cardiac action potential comprises a depolarization, a plateau/refractory, and rapid repolarization phases. The repolarization phase is seen on the ECG as the QTc interval. It is associated with an increase in potassium permeability, which moves potassium out of the cardiac cell. This repolarizing potassium current, the delayed outward rectifier current, has a rapidly activating component and a slowly activating component.<xref ref-type="bibr" rid="article-23809.r4">[4]</xref>&#x000a0;Mutations in the&#x000a0;<italic toggle="yes">KCNQ1</italic>&#x000a0;and&#x000a0;<italic toggle="yes">KCNE1</italic>&#x000a0;genes encode the alpha and beta subunits of the slowly activating components resulting in a slower movement of potassium outside the cell, which prolongs the QTc interval.<xref ref-type="bibr" rid="article-23809.r2">[2]</xref></p>
      </sec>
      <sec id="article-23809.s6" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>Classically, JLNS is suspected in a deaf child who experiences syncopal episodes that are often precipitated by emotion or exercise. Fifty percent of patients have a cardiac event by age three. Other pertinent clues are a history of iron deficiency anemia and elevated gastrin levels.<xref ref-type="bibr" rid="article-23809.r2">[2]</xref>&#x000a0;A physical exam is mostly unremarkable other than deafness.</p>
      </sec>
      <sec id="article-23809.s7" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>Once JLNS is suspected in a child with congenital deafness and syncopal episodes, the next step is to evaluate the QTc interval to check if it is longer than 500 msec. Identifying the pathogenic variants in either the&#x000a0;<italic toggle="yes">KCNQ1</italic>&#x000a0;or&#x000a0;<italic toggle="yes">KCNE1</italic>&#x000a0;confirms the diagnosis. Testing for the genes can either be done as a single-gene test, a multigene panel, or comprehensive genomic testing.<xref ref-type="bibr" rid="article-23809.r2">[2]</xref></p>
        <p>Once the diagnosis is established, the extent of the disease should be assessed. Evaluation should include a formal audiology evaluation, geneticist consultation, complete blood count to look for anemia, thorough family history.<xref ref-type="bibr" rid="article-23809.r2">[2]</xref></p>
      </sec>
      <sec id="article-23809.s8" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>The first-line therapy in preventing syncope, cardiac arrest, and sudden death is a beta-blockade. Propranolol and nadolol have been shown to be superior to metoprolol in preventing cardiac events. The current consensus is that nadolol as the most preferred.<xref ref-type="bibr" rid="article-23809.r5">[5]</xref>&#x000a0;In patients with a history of cardiac arrest, an implantable cardioverter-defibrillator (ICD) should be placed. Other indications for ICD placement is in patients who are deemed high risk. These include a QTc interval greater than 550 msec, syncope before age 5, and a male older than 20 years with the&#x000a0;<italic toggle="yes">KCNQ1</italic>&#x000a0;pathogenic variant.<xref ref-type="bibr" rid="article-23809.r6">[6]</xref></p>
        <p>Despite beta-blocker therapy in symptomatic pediatric patients, Fruh et al. from Norway endorse the combined modality of atrial pacemaker and beta-blocker.<xref ref-type="bibr" rid="article-23809.r7">[7]</xref></p>
        <p>Hearing loss is usually treated successfully with cochlear implantation.<xref ref-type="bibr" rid="article-23809.r8">[8]</xref></p>
        <p>Anesthesia for any surgical procedure has implications in a patient with JLNS. Any trigger to arrhythmia, including sympathetic overdrive, hypo- or hyperthermia, hypovolemia, and hypercarbia, should be carefully avoided. High airway pressure should be avoided. Beta-blockers should be readily available along with equipment for immediate transcutaneous or transvenous pacing and defibrillation.</p>
      </sec>
      <sec id="article-23809.s9" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>The other most common etiologies of long QT syndromes, which must be considered in the differential diagnosis, include the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>Romano-Ward syndrome (RWS) is an autosomal dominant syndrome characterized by a prolonged QTc interval in the absence of congenital deafness. The mechanism of action is similar to JLNS in that it also affects the sodium and potassium channels. The diagnosis of RWS is made based on a prolonged QT interval on ECG, clinical presentation, and family history. The most common genes associated with the syndrome are&#x000a0;<italic toggle="yes">KCNQ1</italic>,&#x000a0;<italic toggle="yes">KCNH2</italic>, and&#x000a0;<italic toggle="yes">SCN5A</italic>. Only the&#x000a0;<italic toggle="yes">KCNQ1</italic>&#x000a0;and&#x000a0;<italic toggle="yes">KCNE1</italic>&#x000a0;genes have been linked to both JLNS and RWS.<xref ref-type="bibr" rid="article-23809.r9">[9]</xref></p>
          </list-item>
          <list-item>
            <p>Timothy syndrome is a rare autosomal disease characterized by:
<list list-type="bullet"><list-item><p>Cardiac abnormal rhythm including QTc prolongation, functional 2:1 AV block with bradycardia, tachyarrhythmias,</p></list-item><list-item><p>Congenital heart defects (patent ductus arteriosus, patent foramen ovale, ventricular septal defect, tetralogy of Fallot, hypertrophic cardiomyopathy)</p></list-item><list-item><p>Syndactyly,</p></list-item><list-item><p>Developmental delays, autism spectrum disorders.</p></list-item></list>
</p>
          </list-item>
        </list>
        <p>The diagnosis is made by clinical features and a defective&#x000a0;<italic toggle="yes">CACNA1C</italic>&#x000a0;gene, which encodes a calcium channel. The prognosis is dismal, with an average age of death in patients with this disease is 2.5 years.<xref ref-type="bibr" rid="article-23809.r10">[10]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>Andersen Tawil syndrome is also a rare autosomal dominant disorder characterized by a triad of :
<list list-type="bullet"><list-item><p>Episodic flaccid paralysis,&#x000a0;</p></list-item><list-item><p>Prolonged QT interval/ventricular arrhythmias</p></list-item><list-item><p>Physical abnormalities including low-set ears, hypertelorism (widely spaced eyes), small jaw, fifth-digit clinodactyly, syndactyly, short stature, and scoliosis.&#x000a0;</p></list-item></list>
</p>
          </list-item>
        </list>
        <p>The diagnosis is made by clinical characteristics and a pathogenic variant in the&#x000a0;<italic toggle="yes">KCNJ2</italic>&#x000a0;gene.<xref ref-type="bibr" rid="article-23809.r11">[11]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>Acquired causes of QTc interval prolongation are most often caused by specific drugs (antiarrhythmics, pro-motility, antimicrobial, and antipsychotics), hypokalemia, hypocalcemia and hypomagnesemia.&#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Myocardial problems such as myopathies and ischemia and central nervous system injuries.<xref ref-type="bibr" rid="article-23809.r12">[12]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-23809.s10" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>More than half of untreated children with JLNS die before age 15.<xref ref-type="bibr" rid="article-23809.r2">[2]</xref>&#x000a0;Prognosis is highly dependent on which gene is mutated, gender, and baseline QTc. Mutations in the&#x000a0;<italic toggle="yes">KCNE1</italic>&#x000a0;genes are associated with a more benign course. Lower risk individuals include females with a QTc less than 550 msec. Goldenberg et al., in their review of high-risk Long QT syndrome patients, showed that Implanted cardioverter-defibrillator protects against JNLS related mortality.<xref ref-type="bibr" rid="article-23809.r13">[13]</xref>&#x000a0;Starting beta-blocker therapy early in the disease state is associated with fewer cardiac events and improved mortality.<xref ref-type="bibr" rid="article-23809.r6">[6]</xref></p>
      </sec>
      <sec id="article-23809.s11" sec-type="Complications">
        <title>Complications</title>
        <p>Complications of untreated disease can lead to syncope, cardiac arrest, and sudden death.<xref ref-type="bibr" rid="article-23809.r2">[2]</xref></p>
      </sec>
      <sec id="article-23809.s12" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Jervell and Lange Nielsen Syndrome (JLNS) is a rare inherited disorder affecting the heart's electrical system and ears. Symptoms are often seen at an early age and include episodes of fainting spells associated with intense emotion and exercise and also hearing loss. The treatment of JLNS is aimed at fixing the hearing loss and preventing further attacks of unconsciousness called syncope or possibly cardiac arrest. The hearing loss is corrected by a medical device called a cochlear implant, which stimulates the brain's nerve that recognizes sounds. A medication class called beta-blockers treat the cardiac abnormalities. These medications decrease the electrical stimulation to the heart and help prevent further abnormal rhythms that can lead to unconsciousness. If the medications fail or if an individual falls into a high-risk category, a device called an implantable automatic cardioverter-defibrillator is usually placed. This device detects an abnormal rhythm and sends an electrical shock to the heart, preventing syncope. Regular follow-up with the patient's pediatrician/primary care doctor and cardiologist is essential in preventing complications. Genetic evaluation of the patient and the family members is recommended.</p>
      </sec>
      <sec id="article-23809.s13" sec-type="Pearls and Other Issues">
        <title>Pearls and Other Issues</title>
        <p>Jervell and Lange-Nielsen syndrome (JLNS) is a rare autosomal recessive disorder that classically presents in a deaf child with recurrent syncopal episodes. It is a form of a prolonged QT syndrome that is characterized by a QTc greater than 500 msec and bilateral sensorineural hearing loss. Cardiovascular complications are managed with beta-blockade (preferably with nadolol) and ICD evaluation. Hearing loss is treated with cochlear implantation. Differential diagnoses of JLNS include Romano-Ward syndrome, Timothy syndrome, Andersen Tawil syndrome, and acquired causes such as electrolyte abnormalities and drugs.</p>
      </sec>
      <sec id="article-23809.s14" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>JLNS is a disorder that is usually caught early in life and requires an interprofessional approach in treating the patient. (Level V) This is generally started with the pediatrician who initially diagnoses the disease and coordinates the care between the interprofessional team, including:</p>
        <list list-type="bullet">
          <list-item>
            <p>Electrophysiology in determining appropriate medical therapy, ICD appropriateness, and activity restrictions</p>
          </list-item>
          <list-item>
            <p>Audiology to assess the extent of hearing loss</p>
          </list-item>
          <list-item>
            <p>Ear, nose, and throat (ENT) physician for cochlear implantation</p>
          </list-item>
          <list-item>
            <p>Geneticist to determine appropriate molecular genetic testing and evaluating family at risk</p>
          </list-item>
        </list>
        <p>As morbidity and mortality are high in patients with this disease, regular assessment of patient's cardiovascular needs will be necessary. This comprises beta-blocker dose adjustments and ICD placement evaluation. Once an ICD is placed, periodic evaluation of inappropriate shocks and lead complications is indicated.<xref ref-type="bibr" rid="article-23809.r2">[2]</xref></p>
      </sec>
      <sec id="article-23809.s15">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=23809&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=23809">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/genetic-disorders/jervell-and-lange-nielsen-syndrome/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=23809">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/23809/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=23809">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-23809.s16">
        <fig id="article-23809.image.f1" position="float" orientation="portrait">
          <caption>
            <p>Prolonged QT Interval Image courtesy S Bhimji MD</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="QTInterval1" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-23809.s17">
        <title>References</title>
        <ref id="article-23809.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>JERVELL</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>LANGE-NIELSEN</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Congenital deaf-mutism, functional heart disease with prolongation of the Q-T interval and sudden death.</article-title>
            <source>Am Heart J</source>
            <year>1957</year>
            <month>Jul</month>
            <volume>54</volume>
            <issue>1</issue>
            <fpage>59</fpage>
            <page-range>59-68</page-range>
            <pub-id pub-id-type="pmid">13435203</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23809.r2">
          <label>2</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Tranebj&#x000e6;rg</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Samson</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Green</surname>
                <given-names>GE</given-names>
              </name>
            </person-group>
            <chapter-title>Jervell and Lange-Nielsen Syndrome</chapter-title>
            <person-group person-group-type="editor">
              <name>
                <surname>Adam</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Feldman</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Mirzaa</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Pagon</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Wallace</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Amemiya</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <source>GeneReviews<sup>&#x000ae;</sup> [Internet]</source>
            <publisher-name>University of Washington, Seattle</publisher-name>
            <publisher-loc>Seattle (WA)</publisher-loc>
            <year>2002</year>
            <month>7</month>
            <day>29</day>
            <pub-id pub-id-type="pmid">20301579</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23809.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Uysal</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Turkgenc</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Toksoy</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Bostan</surname>
                <given-names>OM</given-names>
              </name>
              <name>
                <surname>Evke</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Uyguner</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Yakicier</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Kayserili</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Cil</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Temel</surname>
                <given-names>SG</given-names>
              </name>
            </person-group>
            <article-title>"Homozygous, and compound heterozygous mutation in 3 Turkish family with Jervell and Lange-Nielsen syndrome: case reports".</article-title>
            <source>BMC Med Genet</source>
            <year>2017</year>
            <month>Oct</month>
            <day>16</day>
            <volume>18</volume>
            <issue>1</issue>
            <fpage>114</fpage>
            <pub-id pub-id-type="pmid">29037160</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23809.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shih</surname>
                <given-names>HT</given-names>
              </name>
            </person-group>
            <article-title>Anatomy of the action potential in the heart.</article-title>
            <source>Tex Heart Inst J</source>
            <year>1994</year>
            <volume>21</volume>
            <issue>1</issue>
            <fpage>30</fpage>
            <page-range>30-41</page-range>
            <pub-id pub-id-type="pmid">7514060</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23809.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ackerman</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Priori</surname>
                <given-names>SG</given-names>
              </name>
              <name>
                <surname>Dubin</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Kowey</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Linker</surname>
                <given-names>NJ</given-names>
              </name>
              <name>
                <surname>Slotwiner</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Triedman</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Van Hare</surname>
                <given-names>GF</given-names>
              </name>
              <name>
                <surname>Gold</surname>
                <given-names>MR</given-names>
              </name>
            </person-group>
            <article-title>Beta-blocker therapy for long QT syndrome and catecholaminergic polymorphic ventricular tachycardia: Are all beta-blockers equivalent?</article-title>
            <source>Heart Rhythm</source>
            <year>2017</year>
            <month>Jan</month>
            <volume>14</volume>
            <issue>1</issue>
            <fpage>e41</fpage>
            <page-range>e41-e44</page-range>
            <pub-id pub-id-type="pmid">27659101</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23809.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schwartz</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Spazzolini</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Crotti</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Bathen</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Amlie</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Timothy</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Shkolnikova</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Berul</surname>
                <given-names>CI</given-names>
              </name>
              <name>
                <surname>Bitner-Glindzicz</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Toivonen</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Horie</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Schulze-Bahr</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Denjoy</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>The Jervell and Lange-Nielsen syndrome: natural history, molecular basis, and clinical outcome.</article-title>
            <source>Circulation</source>
            <year>2006</year>
            <month>Feb</month>
            <day>14</day>
            <volume>113</volume>
            <issue>6</issue>
            <fpage>783</fpage>
            <page-range>783-90</page-range>
            <pub-id pub-id-type="pmid">16461811</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23809.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fr&#x000fc;h</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Siem</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Holmstr&#x000f6;m</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>D&#x000f8;hlen</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Haugaa</surname>
                <given-names>KH</given-names>
              </name>
            </person-group>
            <article-title>The Jervell and Lange-Nielsen syndrome; atrial pacing combined with &#x000df;-blocker therapy, a favorable approach in young high-risk patients with long QT syndrome?</article-title>
            <source>Heart Rhythm</source>
            <year>2016</year>
            <month>Nov</month>
            <volume>13</volume>
            <issue>11</issue>
            <fpage>2186</fpage>
            <page-range>2186-2192</page-range>
            <pub-id pub-id-type="pmid">27451284</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23809.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Green</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Schuh</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Maddern</surname>
                <given-names>BR</given-names>
              </name>
              <name>
                <surname>Haymond</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Helffrich</surname>
                <given-names>RA</given-names>
              </name>
            </person-group>
            <article-title>Cochlear implantation in Jervell and Lange-Nielsen syndrome.</article-title>
            <source>Ann Otol Rhinol Laryngol Suppl</source>
            <year>2000</year>
            <month>Dec</month>
            <volume>185</volume>
            <fpage>27</fpage>
            <page-range>27-8</page-range>
            <pub-id pub-id-type="pmid">11140992</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23809.r9">
          <label>9</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Groffen</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Bikker</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Christiaans</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <chapter-title>Long QT Syndrome Overview</chapter-title>
            <person-group person-group-type="editor">
              <name>
                <surname>Adam</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Feldman</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Mirzaa</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Pagon</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Wallace</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Amemiya</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <source>GeneReviews<sup>&#x000ae;</sup> [Internet]</source>
            <publisher-name>University of Washington, Seattle</publisher-name>
            <publisher-loc>Seattle (WA)</publisher-loc>
            <year>2003</year>
            <month>2</month>
            <day>20</day>
            <pub-id pub-id-type="pmid">20301308</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23809.r10">
          <label>10</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Napolitano</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Timothy</surname>
                <given-names>KW</given-names>
              </name>
              <name>
                <surname>Bloise</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Priori</surname>
                <given-names>SG</given-names>
              </name>
            </person-group>
            <chapter-title><italic>CACNA1C</italic>-Related Disorders</chapter-title>
            <person-group person-group-type="editor">
              <name>
                <surname>Adam</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Feldman</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Mirzaa</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Pagon</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Wallace</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Amemiya</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <source>GeneReviews<sup>&#x000ae;</sup> [Internet]</source>
            <publisher-name>University of Washington, Seattle</publisher-name>
            <publisher-loc>Seattle (WA)</publisher-loc>
            <year>2006</year>
            <month>2</month>
            <day>15</day>
            <pub-id pub-id-type="pmid">20301577</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23809.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nguyen</surname>
                <given-names>HL</given-names>
              </name>
              <name>
                <surname>Pieper</surname>
                <given-names>GH</given-names>
              </name>
              <name>
                <surname>Wilders</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Andersen-Tawil syndrome: clinical and molecular aspects.</article-title>
            <source>Int J Cardiol</source>
            <year>2013</year>
            <month>Dec</month>
            <day>05</day>
            <volume>170</volume>
            <issue>1</issue>
            <fpage>1</fpage>
            <page-range>1-16</page-range>
            <pub-id pub-id-type="pmid">24383070</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23809.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kallergis</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Goudis</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Simantirakis</surname>
                <given-names>EN</given-names>
              </name>
              <name>
                <surname>Kochiadakis</surname>
                <given-names>GE</given-names>
              </name>
              <name>
                <surname>Vardas</surname>
                <given-names>PE</given-names>
              </name>
            </person-group>
            <article-title>Mechanisms, risk factors, and management of acquired long QT syndrome: a comprehensive review.</article-title>
            <source>ScientificWorldJournal</source>
            <year>2012</year>
            <volume>2012</volume>
            <fpage>212178</fpage>
            <pub-id pub-id-type="pmid">22593664</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23809.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Goldenberg</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Moss</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Zareba</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>McNitt</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Robinson</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Qi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Towbin</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Ackerman</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Murphy</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Clinical course and risk stratification of patients affected with the Jervell and Lange-Nielsen syndrome.</article-title>
            <source>J Cardiovasc Electrophysiol</source>
            <year>2006</year>
            <month>Nov</month>
            <volume>17</volume>
            <issue>11</issue>
            <fpage>1161</fpage>
            <page-range>1161-8</page-range>
            <pub-id pub-id-type="pmid">16911578</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
